Modification of lipoproteins in diabetes

Diabetes/Metabolism Reviews

Volumn 12, Issue 1, 1996, Pages 69-90

  Lopes Virella, Maria F ^a   Klein, Richard L ^b   Virella, Gabriel ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ATHEROSCLEROSIS; DIABETES MELLITUS; HUMAN; LIPID METABOLISM; PRIORITY JOURNAL; REVIEW;

EID: 0029974779     PISSN: 07424221     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-0895(199603)12:1<69::AID-DMR158>3.0.CO;2-B     Document Type: Review

References (180)

1. Bellamy MF, Nealis AS, Aitken JW, Bruckdorfer KR, and Perkins SJ: Structural changes in oxidized low-density lipoproteins and of the effect of the anti-atherosclerotic drug probucol observed by synchrotron X-ray and neutron solution scattering. Eur J Biochem 183: 321-329, 1989.
2. Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, and Steinberg D: Modification of LDL by endothelial cells involves lipid peroxidation and degrdation of LDL phospholipids. Proc Natl Acad Sci USA 81: 3883-3887, 1984.
3. Freeman M, Ekkel Y, and Rohrer L: Expression of type I and type II bovine scavenger receptors in Chinese hamster ovary cells: lipid droplet accumulation and non-reciprocal cross competition by acetylated and oxidized LDL. Proc Natl Acad Sci USA 88: 4931-4936, 1991.
4. Perm MS, and Chisolm GM: Oxidized lipoproteins, altered cell function and atherosclerosis. Atherosclerosis 108: S21-29, 1994.
5. Henriksen T, Mahoney EM, and Steinberg D: Enhanced macrophage degradation of LDL previously incubated with cultured endothelial cells: recognition by receptors for acetylated LDL. Proc Natl Acad Sci USA 78: 6499-6503, 1981.
6. Arai K, Kita T, Yokode M, Narumiya S, and Kawai C: Multiple receptors for modified LDL in mouse peritoneal macrophages: different uptake mechanisms for acetylated and oxidized LDL. Biochem Biophys Res Commun 159: 1375-1379, 1989.
7. Endemann G, Stanton LW, Madden KS, Bryant CM, White RT, and Frotter AA: CD36 is a receptor for oxidized LDL. J Biol Chem 268: 11811-11818, 1993.
8. Stanton LW, White RT, Bryant CM, Frotter AA, and Endemann G: A macrophage Fc receptor for IgG is also a receptor for oxidized LDL. J Biol Chem 267: 22446-22451, 1992.
9. Sparrow CP, Parthasarathy S, and Steinberg D: A macrophage receptor that recognizes oxidized LDL but not acetylated LDL. J Biol Chem 264: 2599-2603, 1989.
10. James RW, and Pometta D: Differences in lipoprotein subfraction composition and distribution between type I diabetic men and control subjects. Diabetes 39: 1158-1164, 1990.
11. James RW, and Pometta D: The distribution profiles of very low density and low density lipoproteins in poorly-controlled male, type 2 (non-insulin-dependent) diabetic patients. Diabetologia 34: 246-252, 1991.
12. de Graaf J, Hak-Lemmers HLM, Hectors MPC, Demacker PNM, Hendriks JCM, and Stalenhoef AFH: Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arteriosclerosis Thromb 11: 298-306, 1991.
13. Tomkin G, and Owens D: Insulin and lipoprotein metabolism with special reference to the diabetic state. Diabetes/Metab Rev 10: 225-252, 1994.
14. Lahdenpera S, Groop PH, Tilly-Kiesi M, Kuusi T, Elliott TG, Viberti GC, and Taskinen MR: LDL subclasses in IDDM patients: relation to diabetic nephropathy. Diabetologia 37: 681-688, 1994.
15. Regnstrom J, Nilsson J, Tornvall P, Landou C, and Hamsten A: Susceptibility to LDL oxidation and coronary atherosclerosis in man. Lancet 339: 1183-1186, 1991.
16. -. Lopes-Virella MF, Wohltmann H, Mayfield R, Loadholt CB, and Colwell JA: Effect of metabolic control on lipid, lipoprotein and apolipoprotein levels in 55 IDDM patients: a longitudinal study. Diabetes 32: 20-25, 1983.
17. Baynes JW: Role of oxidative stress in development of complications in diabetes. Diabetes 40: 405-412, 1991.
18. Ahmed MU, Thorpe SR, and Baynes JW: Identification of carboxymethyllysine as a degradation product of fructose-lysine in glycated protein. J Biol Chem 261: 4889-4994, 1986.
19. Ahmed MU, Dunn JA, Walla MD, Thorpe SR, and Baynes JW: Oxidative degradation of glucose adducts to protein: formation of 3-(N epsilon-lysino)-lactic acid from model compounds and glycated proteins. J Biol Chem 263: 8816-8821, 1988.
20. Sell DR, and Monnier VM: Structure elucidation of a senescence cross-link from human extra-cellular matrix: implication of pentoses in the aging process. J Biol Chem 264: 21597-21602, 1989.
21. Fu M-X, Knecht KJ, Lyons TJ, Thorpe SR, and Baynes JW: Role of oxygen in the cross-linking and chemical modification of collagen by glucose. Diabetes 43: 676-683, 1994.
22. Reaven PD, Picard S, and Witztum JL: LDL metabolism in diabetes. In Diabetes and Atherosclerosis, Draznin B, and Eckel R (Eds). Elsevier, Amsterdam, 1993, pp 17-38.
23. Bucala R, Makita Z, Koschinsky T, Cerami A, and Vlassara H: Lipid advanced glycation: pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 90: 6434-6438, 1993.
24. Wolff SP, and Dean RT: Glucose autoxidation and protein modification: the potential role of "autoxidative glycation" in diabetes mellitus. Biochem J 245: 243-250, 1987.
25. Kennedy L, and Baynes JW: Non-enzymatic glycosylation and the chronic complications of diabetes: an overview. Diabetologia 26: 93-98, 1984.
26. Witztum JL, Steinbrecher UP, Kesaniemi YA, and Fisher M: Autoantibodies to glucosylated proteins in the plasma of patients with diabetes mellitus. Proc Natl Acad Sci USA 81: 3204-3208,1984.
27. Palinski W, Rosenfeld ME, Yla-Herttuala S, Gurtner GC, Socher SS, Butler SW, Parthasarathy S, Carew TE, Steinberg D, and Witztum JL: Low density lipoprotein undergoes oxidative modification in vivo. Proc Natl Acad Sci USA 86: 1372-1376, 1989.
28. Brownlee M, Pongor S, and Cerami A: Covalent attachment of soluble proteins by non-enzymatically glycosylated collagen: role in the in situ formation of immune complexes. J Exp Med 158: 1739-1744, 1983.
29. Howard BV: Lipoprotein metabolism in diabetes mellitus. J Lipid Res 28: 613-628, 1987.
30. Brown VW: Lipoprotein disorders in diabetes mellitus. Med Clin North Am 78: 143-161, 1994.
31. Schleicher E, Deufel T, and Wieland OH: Nonenzymatic glycation of human serum lipoproteins. FEES Lett 129: 1-4, 1987.
32. Lyons TJ, Patrick JS, Baynes JW, Colwell JA, and Lopes-Virella MF: Glycation of low density lipoprotein in patients with type 1 diabetes: correlations with other parameters of glycaemic control. Diabetologia 29: 685-689, 1986.
33. Steinbrecher UP, and Witztum JL: Glucosylation of low density lipoproteins to an extent comparable to that seen in diabetes slows their catabolism. Diabetes 33: 130-134, 1984.
34. Witztum JL, Mahoney EM, Branks MJ, Fisher M, Elam R, and Steinberg D: Nonenzymatic glucosylation of low-density lipoprotein alters its biologic activity. Diabetes 31: 283-291, 1982.
35. Nordestgaard BG, and Zilversmit DB: Comparison of arterial intimai clearances of LDL from diabetic and non-diabetic cholesterol fed rabbits: differences in intimai clearances explained by size differences. Arteriosclerosis 9: 176-183, 1989.
36. Kortland W, Benschop C, van Rijn HJM, and Erkelens DW: Glycated LDL catabolism is increased in rabbits with alloxan-induced diabetes mellitus. Diabetologia 35: 202-207, 1992.
37. Pietri A, Dunn FL, and Raskin P: The effect of improved diabetic control on plasma lipid and lipoprotein levels: a comparison of conventional therapy and subcutaneous insulin infusion. Diabetes 29: 1001-1005, 1980.
38. Dunn PL, Pietri A, and Raskin P: Plasma lipid and lipoprotein levels with continuous subcutaneous insulin infusion in type I diabetes mellitus. Ann Intern Med 95: 426-431, 1981.
39. Pietri A, Dunn FL, and Grundy SM: The effect of continuous subcutaneous insulin infusion on VLDL triglyceride metabolism in type I diabetes mellitus. Diabetes 32: 75-81, 1983.
40. Abrams JJ, Ginsberg H, and Grundy SM: Metabolism of cholesterol and plasma triglycerides in nonketotic diabetes mellitus. Diabetes 31: 903-910, 1982.
41. Dunn FL, Raskin P, and Bilheimer DW: The effect of diabetic control on very low density lipoprotein-triglyceride metabolism in patients with type II diabetes mellitus and marked hypertriglyceridemia. Metabolism 33: 117-123, 1984.
42. Steinbrecher UP, Witztum JL, and Kesaniemi YA: Comparison of glycosylated LDL with methylated or cyclohexandione-treated LDL in the measurement of receptor independent LDL catabolism. J Clin Invest 71: 960-964, 1983.
43. Kesaniemi YA, Witztum JL, and Steinbrecher UP: Receptor-mediated clearance of LDL in man: new estimates using glycosylated LDL. J Clin Invest 71: 950-959, 1983.
44. Wiklund O, Witztum JL, and Carew TE: Turnover and tissue sites of degradation of glycosylated LDL in normal and immunized rabbits. J Lipid Res 28: 1098-1109, 1987.
45. Weisgraber KH, Innerarity TL, and Mahley RW: Role of the lysine residues of plasma lipoproteins in high affinity binding to cell surface receptors on human fibroblasts. J Biol Chem 253: 9053-9062, 1978.
46. Gonen B, Baenziger J, Schonfeld G, Jacobsen D, and Farrar P: Non-enzymatic glycation of low-density lipoproteins in vitro. Diabetes 30: 875-878, 1981.
47. Sasaki J, and Cottam GL: Glycation of LDL decreases its ability to interact with high-affinity receptors of human fibroblasts in vitro and decreases its clearance from rabbit plasma in vivo. Biochim Biophys Acta 713: 199-207, 1982.
48. Lopes-Virella MF, Sherer GK, Lees AM, Wohltmann H, Mayfield R, Sagel J, Leroy EC, and Colwell JA: Surface binding, internalization and degradation by cultured human fibroblasts of low density lipoproteins isolated from type I (insulin-dependent) diabetic patients: changes with metabolic control. Diabetologia 22: 430-436, 1982.
49. Lopes-Virella MF, Klein RL, Lyons TJ, Stevenson HC, and Witztum JL: Glycation of low-density lipoprotein enhances chqlesteryl ester synthesis in human monocyte-derived macrophages. Diabetes 37: 550-557, 1988.
50. Lyons TJ, Klein RL, Baynes JW, Stevenson HC, and Lopes-Virella MF: Stimulation of choles- teryl ester synthesis in human monocyte-derived macrophages by low-density lipoproteins from type I (insulin-dependent) diabetic patients: the influence of non-enzymatic glycation of low-density lipoprotein. Diabetologia 30: 916-923, 1987.
51. Klein RL, Lyons TJ, and Lopes-Virella MF: Metabolism of very low- and low density lipoproteins isolated from normolipidaemic type 2 (non-insulin-dependent) diabetic patients by human monocyte-derived macrophages. Diabetologia 33: 299-305, 1990.
52. Klein RL, Laimins M, and Lopes-Virella MF: Isolation, characterization and metabolism of the glycated and non-glycated subfractions of low density lipoproteins isolated from type 1 diabetic patients and non-diabetic subjects. Diabetes 44: 1093-1098, 1995.
53. Jack CM, Sheridan B, Kennedy L, and Stout RW: Non-enzymatic glycation of low-density lipoprotein: results of an affinity chromatography method. Diabetologia 31: 126-128, 1988.
54. Watanabe L Wohltrnann HJ, Klein RL, Colwell JA, and Lopes-Virella MF: Enhancement of platelet aggregation by low density lipoproteins from IDDM patients. Diabetes 37: 1652-1657, 1988.
55. Jokl R, Klein RL, Colwell JA, and Virella MF: Low density lipoproteins isolated from diabetic patients alter the release of tissue plasminogen activator (tPA) by cultured human endothelial cells. Diabetes 41 (Suppl 1): 113A, 1992.
56. Kahn BV, Parthasarathy SS, Alexander RW, and Medford RM: Modified LDL and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells. J Clin Invest 95: 1262-1270, 1995.
57. Curtiss LK, and Witztum JL: Plasma apo-lipoproteins A-I, A-II, B, C-I and E are glucosylated in hyperglycemice diabetic subjects. Diabetes 34: 452-465, 1985.
58. Klein RL, Lyons TJ, and Lopes-Virella MF: Interaction of very-low-density lipoprotein isolated from type 1 (insulin-dependent) diabetic subjects with human monocyte-derived macrophages. Metabolism 38: 1108-1114, 1989.
59. Witztum JL, Fisher M, Pietro T, Steinbrecher UP, and Elam RL: Nonenzymatic glucosylation of high-density lipoprotein accelerates its catabolism in guinea-pigs. Diabetes 31: 1029-1032, 1982.
60. Duell PB, Oram JF, and Bierman EL: Nonenzymatic glycation of HDL resulting in inhibition of high-affinity binding to cultured human fibroblasts. Diabetes 39: 1257-1263, 1990.
61. Duell PB, Oram JF, and Bierman EL: Nonenzymatic glycation of HDL and impaired HDL-receptor-mediated cholesterol efflux. Diabetes 40: 377-384,1991.
62. Hunt JV, Smith CCT, and Wolff SP: Autooxidative glycation and possible involvement of per- oxides and free radicals in LDL modification by glucose. Diabetes 39: 1420-1424, 1990.
63. Kawamura M, Heinecke JW, and Chait A: Pathophysiological concentrations of glucose promote oxidative modification of LDL by a superoxide-dependent pathway. J Clin Invest 94: 771-778, 1994.
64. Azevedo MS, Raposa J, Falcão J, Fontes G, and Manso C: O2 radical generation by Maillard compounds. J Diabetic Complications 2: 19-21, 1988.
65. Cillery P, Monboisse JC, Maquart FX, and Borel JP: Glycation of proteins as a source of superoxide. Diabetes Metab Rev 14: 25-30, 1988.
66. Mullarkey CJ, Edelstein D, and Brownlee M: Free radical generation by early glycation products: a mechanism for accelerated atherogenesis in diabetes. Biochem Biophys Res Commun 173: 932-939, 1990.
67. Sakurai T, Kimura S, Nakano M, and Kimura H: Oxidative modification of glycated low density lipoprotein in the presence of iron. Biochem Biophys Res Commun 177: 433-439, 1991.
68. Brownlee M, Vlassara H, and Cerami A: Nonenzymatic glycosylation products on collagen covalentiy trap low-density lipoprotein. Diabetes 34: 938-941, 1985.
69. Haberland M, Fong D, and Cheng L: Malondial-dehyde-altered protein occurs in atheroma of Watanabe heritable hyperlipidemic rabbits. Science 241: 215-218, 1988.
70. Rosenfeld M, Palinski W, Yla-Herttuala S, Butler S, and Witztum JL: Distribution of oxidation specific lipid-protein adducts and apolipoprotein B in atherosclerotic lesions of varying severity from WHHL rabbits. Arteriosclerosis 10: 336-349, 1990.
71. Boyd HC, Gown AM, Wolfbauer G, and Chait A: Direct evidence for a protein recognized by a monoclonal antibody against oxidatively modified LDL in atherosclerotic lesions from a WHHL rabbit. Am J Pathol 135: 815-826, 1989.
72. Yla-Herttuala S, Palinski W, Picard S, Butler S, Steinberg D, and Witztum JL: Immunoglobulins extracted from atherosclerotic lesions recognize epitopes of oxidized LDL. Arterioscler Thromb 14: 32-40, 1994.
73. Carew TE, Schwenke DC, and Steinberg D: Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophagerich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA 84: 7725-7729, 1987.
74. Kita T, Nagano Y, Yokode M, Ishii K, Kume N, Ooshima A, Yoshida H, and Kawai C: Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA 84: 5928-5931, 1987.
75. Palinski W, Koschinsky T, Butier S, Miller E, Vlassara H, Cerami A, and Witztum JL. Immunological evidence for the pressure of AGE in atherosclerotic lesions of euglycemic rabbits. Arterioscler Thromb Vase Biol 15: 571-582, 1995.
76. Yla-Herttuala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witztum JL, and Steinberg D: Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 84: 1086-1095, 1989.
77. Clevidence BA, Morton RE, West G, Dusek DM, and Hoff HF: Cholesterol esterification in macrophages: stimulation by lipoproteins containing apo B isolated from human aortas. Arteriosclerosis 4: 196-207, 1984.
78. Hoff HF, and O'Neil J: Lesion-derived LDL and oxidized LDL share a lability for aggregation, leading to enhanced macrophage degradation. Arterioscler Thromb 11: 1209-1222, 1991.
79. Bjorkham I, Henricksson-Freyschuss A, Breuer O, Diczfalusy U, Berglund L, and Henrikson P: The antioxidant butylated hydroxytoluene protects against atherosclerosis. Arterioscler Thromb 11: 15-22, 1991.
80. Sparrow CP, Doebber TW, Olszewski J, Wu MS, Ventre J, Stevens KA, and Chao YS: LDL is protected from oxidation and the progression of atherosclerosis is slowed in cholesterol-fed rabbits by the antioxidant N,N'-diphenyl-phenylenediamine. J Clin Invest 89: 1885-1891, 1992.
81. Chiu H-C, Jeng J-R, and Shieh S-M: Increased oxidizability of plasma LDL from patients with coronary heart disease. Biochim Biophys Acta 225: 200-208, 1994.
82. Cominacini L, Garbi U, Pastorino AM, Davoli A, Campagnola M, De Santis A, Pasini C, Faccini GB, Trevisan MT, Bertozzo L, Pasini F, and LoCascio V: Predisposition to LDL oxidation in patients with and without angiographically established coronary artery disease. Atherosclerosis 99: 63-70, 1993.
83. Andrews B, Burnand K, Paganga G, Browse N, Rice-Evans C, Sommerville K, Leake D, and Taub N: Oxidizability of LDL in patients with carotid or femoral artery atherosclerosis. Atherosclerosis 112: 77-84, 1995.
84. Maggi E, Chiesa R, Melissano G, Castellano R, Astore D, Grossi A, Finardi G, and Bellomo G: LDL oxidation in patients with severe carotid atherosclerosis. Arterioscler Thromb 14: 1892-1899, 1994.
85. Salonen JT, Yla-Herttualas, Yamamoto R, Butler S, Korpela H, Salonen R, Nyyssonen K, Palinski W, and Witztum JL: Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 339: 883-887, 1992.
86. Bowie A, Owens D, Collins P, Johnson A, and Tomkin P: Glycosylated LDL is more sensitive to oxidation: implications for the diabetic patient? Atherosclerosis 102:63-67, 1993.
87. Tsai EC, Hirsch IB, Brunzell JD, and Chait A: Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes 43: 1010-1014, 1994.
88. Jenkins A, Chassereau C, Klein RL, and Lopes-Virella MF: In vitro LDL oxidizability is not increased in patients with well controlled IDDM. Diabetes 44 (Suppl 1): 43a, 1995.
89. Hoff HF, O'Neil J, Chisolm GM, Cole TB, Quehenberger O, Esterbauer H, and Jurgens G: Modification of LDL with 4-hydroxynonenal induces uptake by macrophages. Arteriosclerosis 9: 538-549, 1989.
90. Fogelman AM, Schechter I, Seager J, Hokom M, Child JS, and Edwards PA: Malondialdehyde alteration of LDL leads to cholesterol ester accumulation in human monocytes/ macrophages. Proc Natl Acad Sci USA 77: 2214-2218, 1980.
91. Vlassara H, Brownlee M, and Cerami A: Novel macrophage receptor for glucose-modified proteins is distinct from previously described scavenger receptors. J Exp Med 164: 1301-1309, 1986.
92. Vlassara H, Valinsky J, Brownlee M, Cerami C, Nishimoto S, and Cerami A: Advanced glycosylation end products on erythrocyte cell surface induce receptor-mediated phagocytosis by macrophages: a model for turnover of aging cells. J Exp Med 166: 539-549, 1987.
93. Hessler JR, Robertson AL Jr, and Chisolm GM: LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture. Atherosclerosis 32: 213-218, 1979.
94. Henriksen T, Evensen SA, and Carlander B: Injury to human endothelial cells in culture induced by LDL. Scand J Clin Lab Invest 39: 361-364, 1979.
95. Hessler JR, Morel DW, Lewis LJ, and Chisolm GM: Lipoprotein oxidation and lipoprotein-induced cytotoxicity. Arteriosclerosis 3: 215-219, 1983.
96. Morel DW, Hessler JR, and Chisolm GM: LDL cytotoxicity induced by free radical peroxidation of lipid. J Lipid Res 24: 1070-1073, 1983.
97. Negre-Salvayre A, Lopes M, and Levade T: Ultra-violet-treated lipoproteins as a model system for the study of the biological effects of lipid peroxides on cultured cells. II. Uptake and cytotoxicity of ultra-violet treated LDL on lymphoid cells. Biochim Biophys Acta 1045: 224-227, 1990.
98. Gotoh N, Graham A, Nikl E, and Darley-Usmar VM: Inhibition of glutathione synthesis increases the toxicity of oxidized low density lipoprotein to human monocytes and macrophages. Biochem J 296: 151-155, 1993.
99. Jurgens G, Hoff HF, Chisolm GM, and Esterbauer H: Modification of human serum LDL by oxidation: characterization and pathophysiologic implications. Chem Phys Lipids 45: 315-320, 1987.
100. Fox PL, Chisolm GM, and DiCorleto PE: Lipoprotein mediated inhibition of endothelial cell production of platelet-derived growth factor- like proteins depends on free radical lipid peroxidation. J Biol Chem 262: 6046-6049, 1987.
101. Maiden LT, Chail A, Raines EW, and Ross R: The influence of oxidatively modified LDL on expression of platelet derived growth factor by human monocyte-derived macrophages. J Biol Chem 266: 13901-13904, 1991.
102. Hamilton TA, Ma GP, and Chisolm GM: Oxidized LDL suppresses the expression of tumor necrosis factor a mRNA in stimulated rnurine peritoneal macrophages. J Immunol 144: 2343-2348, 1990.
103. Thai SF, Lewis JG, Williams RB, Johnson SP, and Adams DO: Effects of oxidized LDL on mononuclear phagocytes: inhibition of induction of four inflammatory cytokine gene RNAs, release of NO and cytolysis of tumor cells. J leukocyte Biol 57: 427-433, 1995.
104. Rajavashisth TB, Andalibi A, and Territo MC: Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified LDL. Nature 344: 254-257, 1990.
105. Fong LG, Fong TA, and Cooper AD: Inhibition of lipopolysaccharide-induced interleukin-1 b mRNA expression in mouse macrophages by oxidized LDL. J Lipid Res 32: 1899-1903, 1991.
106. Quinn MT, Parthasarathy S, and Steiberg D: Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherosclerosis. Proc Natl Acad Sci USA 85: 2805-2808, 1988.
107. Berliner JA, Territo MC, Sevanian A, Ramin S, Kim JA, Barnshad B, Esterson M, and Fogelman AM: Minimally modified low density lipoprotein stimulates monocyte endothelial interactions. J Clin Invest 85: 1260-1266, 1990.
108. Kume N, Cybulsky MI, and Gimbrone MA Jr: Lysophosphatidyl-choline, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells. J Clin Invest 90: 1138-1144, 1992.
109. Jeng JR, Chang CH, Shieh SM, and Chiu HC: Oxidized LDL enhances monocyte-endothelial cell binding against shear-stress-induced detachment. Biochim Biophys Acta 1178: 221-227, 1993.
110. Gushing SD, Berliner JA, Valente AJ, Territo M, Navab M, Parhami F, Gerrity R, Schwartz CJ, and Fogelman AM: Minimally modified LDL induces monocyte chemotactic proteins I in human endothelial and smooth muscle cells. Proc Natl Acad Sci USA 87: 5134-5138, 1990.
111. Murugesan G, Chisolm GM, and Fox PL: Oxidized LDL inhibits the migration of arterial endothelial cells in vitro. J Cell Biol 120: 1011-1015, 1993.
112. Jougasaki M, Jugiyama K, Saito Y, Nakao K, Imura H, and Yasue H: Suppression of ET-1 secretion by lysophosphatidylcholine in oxidized LDL in cultured vascular endothelial cells. Circulation Res 71: 614-619, 1992.
113. Boulanger CM, Tanner PC, Bea ML, Hahn AW, Werner A, and Luscher TF: Oxidized LDL induces mRNA expression and release of endothelin from human and porcine endothelium. Circ Res 70: 1191-1197, 1992.
114. Liao JK, Shin WS, Lee WY, and Clark SL: Oxidized LDL decreases the expression of endothelial nitric oxide synthase. J Biol Chem 270: 319-324, 1995.
115. Yang X, Cai B, Stiacca RR, and Cannon PJ: Inhibition of inducible nitric oxide synthase in macrophages by oxidized LDL. Circ Res 74: 318-328, 1994.
116. Levin EG, Miles LA, Fless GM, Scanu AM, Baynham P, Curtiss LK, and Plow EF: Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells. Arterioscler Thromb 14: 438-442, 1994.
117. Kugiyama K, Sakamoto T, Musumi I, Sugiyama S, Ohgushi M, Ogawa H, Horiguchi M, and Yasue H: Transferable lipids in oxidized LDL stimulate PAI-1 and inhibit tPA release from endofhelial cells. Circ Res 73: 335-343, 1993.
118. Nagano Y, Arai H, and Kita T: High density lipoprotein loses its effect to stimulate efflux of cholesterol from foam cells after oxidative modification. Proc Natl Acad Sci USA 88: 6457-6461, 1991.
119. Bowry VW, Stanley KK, and Stocker R: High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci USA 89: 10316-10320, 1992.
120. Curtiss LK, and Witztum JL: A novel method of generating region-specific monoclonal antibodies to modified proteins: application to the identification of human glucosylated low density lipoproteins. J Clin Invest 72: 1427-1438, 1983.
121. Witztum JL, Steinbrecher UP, Fisher M, and Kesaniemi A: Nonenzymatic glucosylation of homologous low density lipoprotein and albumin renders them immunogenic in the guineapig. Proc Natl Acad Sci USA 80: 2757-2761, 1983.
122. Salonen JT: Is there a continuing need for longitudinal epidemiologic research? The Kuopio ischaemic heart disease risk factor study. Ann Clin Res 20: 46-50, 1988.
123. Mironova M, Virella G, and Lopes-Virella, MF: Isolation and characterization of human antibodies against oxidized LDL. Arterioscler thromb 16: 222-229, 1996.
124. Beaumont JL: Autoimmune hyperlipidemia: an atherogenic metabolic disease of immune origin. Rev Eur Stud Clin Biol 15: 1037-1041, 1970.
125. Fust G, Szondy E, Szekely J, Nanai I, and Gero S: Studies on the occurrence of circulating immune complexes in vascular disease. Atherosclerosis 29: 181-190, 1978.
126. Szondy E, Lengyel E, Mezey Z, Füst G., and Gero S: Occurrence of anti-low density lipoprotein antibodies and circulating immune com- plexes in aged subjects. Mech Ageing Dev 29: 117-123, 1985.
127. Tertov W, Qrekhov AN, Kacharava AG, Sobenin IA, Perova NV, and Smimov VN: Low density lipoprotein-containing circidating immune complexes and coronary atherosclerosis. Exp Mol Pathol 52: 300-308, 1990.
128. Gisinger C, Virella GT, and Lopes-Virella MF: Erythrocyte-bound low density lipoprotein (LDL) immune complexes lead to cholesteryl ester asccumulation in human monocyte derived macrophages. Clin Immunol Immunopathol 59: 37-52, 1991.
129. Griffith RL, Virella GT, Stevenson HC, and Lopes-Virella MF: LDL metabolism by macrophages activated with LDL immune complexes: a possible mechanism of foam cell formation. J Exp Med 168: 1041-1059, 1988.
130. Klimov AN, Denisenko AD, Popov AV, Nagornev VA, Pleskov VM, Vinogradov AG, Denisenko TV, Magracheva EYa, Kheifes GM, and Kuznetzov AS. Lipoprotein-antibody immune complexes: their catabolism and role in foam cell formation. Atherosclerosis 58:1-15, 1985.
131. Cornacoff JB, Hebert LA, Smead WL, VanAman M, Birmingham DJ, and Waxman FJ: Primate erythrocyte-immune complex-clearing mechanism. J Clin Invest 71: 236-247, 1983.
132. Lopes-Virella MF, Griffith RL, Shunk KA, and Virella GT: Enhanced uptake and impaired intracellular metabolism of low density lipoprotein complexed with anti-low density lipoprotein antibodies. Arterioscler Thromb 11: 1356-1367, 1991.
133. Ross R, Masuda J, Raines E, Gown AM, Katsuda S, Sasahara M, Maiden LT, Masuko H, and Sato H: Localization of PDGF-B protein in macrophages in all phases of atherogenesis. Science 248: 1009-1012, 1990.
134. Nathan CF, Murray HW, and Cohn ZA: The macrophage as an effector cell. N Engl J Med 303: 622-626, 1980.
135. Bonney RJ and Humes JL: Physiological and pharmacological regulation of prostaglandin and leukotriene production by macrophages. J Leukocyte Biol 35: 1-10, 1984.
136. Digeon M, Laver M, Riza J, and Bach JF. Detection of circulating immune complexes in human sera by simplified assays with polyethylene glycol. J Immunol Methods 16: 165-183, 1977.
137. Rouzer CA, Scott WA, Kempe J, and Cohn ZA: Prostaglandin synthesis by macrophages require a specific receptor-ligand interaction. Proc Natl Acad Sci USA 77: 4279-4282, 1980.
138. Stevenson HC, Dekaban GA, Miller PJ, Benyajati C, and Pearson ML: Analysis of human blood monocyte activation at the level of gene expression. J Exp Med 161: 503-513, 1985.
139. Musson RA, Shafran H, and Henson PM: Intracellular levels and stimulated release of lysosomal enzymes from human peripheral blood monpcytes and monocyte-derived macrophages. J Reticuloendothel Soc 28: 249-264, 1980.
140. Werb Z, Bonda MJ, and Jones PA: Degradation of connective tissue matrices by macrophages: I. Proteolysis of elastin, glycoproteins, and collagens by proteinases isolated from macrophages. J Exp Med 152: 1340-1357, 1980.
141. Nakagawara A, Nathan CF, and Cohn ZA: Hydrogen peroxide metabolism in human monocytes during differentiation in vitro. J Clin Invest 68: 1243-1252, 1981.
142. Virella G, Muñoz José F, Galbraith Gillian MP, Gissinger C, Chassereau C, and Lopes-Virella MF: Activation of human monocyte-derived macrophages by immune complexes containing low density lipoprotein. Clin Immunol Immunopathol 75: 179-189, 1995.
143. Chou YK, Sherwood T, and Virella G: Erythrocyte-bound immune complexes trigger the release of interleukin-1 from human monocytes. Cell Immunol 91: 308-314, 1985.
144. Debets JMH, van der Linden CJ, Dieteren IBM, Leeuwenberg JFM, and Buurman WA: Fc-receptor cross-linking induces rapid secretion of tumor necrosis factor (cachectin) by human peripheral blood monocytes. J Immunol 141: 1197-1202, 1988.
145. Luscinskas FW, Brock AF, Arnaout M, and Gimbrone MA: Endothelial-leukocyte adhesion molecule-1-dependent and leukocyte (CDU/ CD18)-dependent mechanisms contribute to polymorphonuclear leukocyte adhesion to cytokine-activated human vascular endothelium. J Immunol 142: 2257-2263, 1989.
146. Bevilacqua MP, Pober JS, Wheeler ME, Cotran RS, and Gimbrone Ma, Jr: Interleukin 1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes, and related leukocyte cell lines. J Clin Invest 76: 2003-2011, 1985.
147. Bevilacqua MP, Stengelin S, Gimbrone MA Jr, and Seed B: Endothelial leukocyte adhesion molecule 1: and inducible receptor for neutrophils related to complement regulatory proteins and lectins. Science 243: 1160-1165, 1989.
148. Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, and Gimbrone MA Jr: Interleukin 1 induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells. J Exp Med 160: 618-622, 1984.
149. Martin S, Maruta K, Burkart V, Gillis S, and Kolb H: IL-1 and INF-g inrease vascular permeability. Immunology 64: 301-305, 1988.
150. Warner SJC, Auger KR, and Libby P: Interleukin 1 induces interleukin. II. Recombinant human interleukin 1 induces interleukin 1 production by adult human vascular endothelial cells. J Immunol 139: 1911-1917, 1987.
151. Breviario F, Bertocchi F, Dejana E, and Bussolino F: IL-1 adhesion of polymorphonuclear leukocytes to cultured human endothelial cells: role of platelet-activating factor. J Immunol 141: 3391-3397, 1988.
152. Zimmerman GA, Prescott SM, and Mclntyre TM: Endothelial cell interactions with granulo- cytes: tethering and signaling molecules. Immunol Today 13: 93-100, 1992.
153. Raines EW, Dower SK, and Ross R: Interleukin-1 mitogenic activity for fibroblasts and smooth muscle cells is due to PDGF-AA. Science 243: 393-396, 1989.
154. Libby P, Warner SJC, and Friedman GB: Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth inhibitory prostanoids. J Clin Invest 81: 487-498, 1988.
155. Cavender D, Saegusa Y, and Ziff M: Stimulation of endothelial cell binding of lymphocytes by tumor necrosis factor. J Immunol 139: 1855-1860, 1987.
156. Gambie JR, Harlan JN, Klebanoff SJ, and Vadas MA: Stimulation of the adherence of neutrophils to umbilical vein endothelium by human recombinant tumor necrosis factor. Proc Natl Acad Sci USA 82: 8667-8671, 1985.
157. Nawroth PP, Bank I, Hadley D, Cassimeris J, Chess L, and Stern D: Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med 165: 1363-1375, 1986.
158. Cerami A, and Beutler B: The role of cachectin/TNF in endotoxic shock and cachexia. Immunol Today 9: 28-31, 1988.
159. Chait A, Iverius PH, and Brunzell JD: Lipoprotein lipase secretion by human monocyte-derived macrophages. J Clin Invest 69: 490-493, 1982.
160. Jonasson L, Bondjers G, and Hansson GK: Lipoprotein lipase in atherosclerosis: its presence in smooth muscle cells and absence from macrophages. J Lipid Res 28: 437-445, 1987.
161. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986, 1993.
162. Esterbauer H, Dieber:Totheneder M, Striegl G, and Waeg G: Role of vitamin E in preventing the oxidation of LDL. Am J Clin Nutr 53: 314S-321S, 1991.
163. Demacker PNM, Hijmans AGM, Kleinveld HA, and Stalenhoef AFH: VHHL rabbits treated with antioxidants: indications for the presence of circulating peroxidized LDL. Atherosclerosis 102: 69-77, 1993.
164. Steinberg D, Parthasarathy S, and Carew TE: In vivo inhibition of foam cell development by probucol in Watanabe rabbits. Am J Cardiol 62: 6B-12B, 1988.
165. Nagano Y, Nakamura T, Matsuzawa Y, Cho M, Ueda Y, and Kita T: Probucol and atherosclerosis in the WHHL rabbit: long term anti-atherogenic effect on established plaques. Atherosclerosis 92: 131-140, 1992.
166. Williams RJ, Motteram JM, Sharp CH, and Gallagher PJ: Dietary vitamin E and the attenuation of early lesion development in modified Watanabe rabbits. Atherosclerosis 94: 153-159, 1992.
167. Suzukawa M, Ishikawa T, Yoshida H, and Nakamura H: Effect of in-vivo supplementation with low dose vitamin E on susceptibility of LDL and HDL to oxidative modification. J Am Coll Nutr 14: 46-52, 1995.
168. Kleinveld HA, Demacker PNM, and Stalenhoef AFH: Comparative study on the effect of low dose vitamin E and probucol on the susceptibility of LDL to oxidation and the progression of atherosclerosis in WHHL rabbits. Arterioscler Thromb 14: 1386-1391, 1994.
169. Frei B, England L, and Ames BN: Ascorbate is an outstanding antioxidant in human plasma. Proc Natl Acad Sci USA 86: 6377-6381, 1989.
170. Som S, Basu S, Mukherjee D, Deb S, Choudhury PR, Mukherjee S, Chatterjee SN, and Chatterjee IB: Ascorbic acid metabolism in diabetes mellitus. Metabolism 30: 572-577, 1981.
171. Jennings PE, Chirico S, Jones AF, Lunec J, and Barnett AH: Vitamin C metabolites and microangiopathy in diabetes mellitus. Diabetes Res 6: 151-154, 1987.
172. Karpen CW, Cataland S, O'Dorisio TM, and Panganamala RV: Production of 12 HETE and vitamin E status in platelets from type 1 human diabetic subjects. Diabetes 34: 526-531, 1985.
173. Reaven P, Parthasarthy S, Grasse BJ, Miller E, Steinberg D, and Witztum JL: Effects of oleate-rich and linoleate-rich diets on the susceptibility of LDL to oxidative modification in mildly hypercholesterolemic subjects. J Clin Invest 91: 668-676, 1993.
174. Reaven PD, Grasse BJ, and Tribble DL: Effects of linoleate enriched and oleate enriched diets in combination with alpha tocopherol on the susceptibility of LDL and LDL subfractions to oxidative modification in humans. Arterioscler Thromb 14: 557-566, 1994.
175. Brownlee M, Vlassara H, Kooney A, Ulrich P, and Cerami A: Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 232: 1629-1632, 1986.
176. Requena JR: The main mechanism of action of aminoguanidine. Dtabetolagia 34 (Suppl2): A162, 1991.
177. Lewis BS and Harding JJ: The effects of aminoguanidine on the glycation (non-enzymic glycosylation) of lens proteins. Exp Eye Res 50: 463-467, 1990.
178. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, and Jerums G: Retardation by aminoguanidine of development of albuminuria, mesangial expansion and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 40: 1328-1334, 1991.
179. Picard S, Parthasarathy S, Fruebis J, and Witztum JL: Aminoguanidine inhibits oxidative modification of LDL protein and the subsequent increase in uptake by macrophage scavenger receptors. Proc Natl Acad Sci USA 89: 6876-6880, 1992.
180. Philis-Tsimikas A, Parthasarathy S, Picard S, Palinski W, and Witztum JL: Aminoguanidine has both pro-oxidant and antioxidant activity toward LDL. Arterioscler Thromb Vase Biol 15: 367-376, 1995.